After a recent court win for its inhaled pulmonary arterial hypertension drug, pushing off competition for a few more years, United Therapeutics has quietly scrapped a late-stage study of Tyvaso.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,